Annual Report from Cyxone AB for the period 1 January 2019 to 31 December 2019
Cyxone AB’s Annual Report for the financial year 2019 is now available at the company’s website (www.cyxone.com).Please see attached Annual Report as pdf. ContactOla Skanung, interim CEO & CFOTel: +46 (0) 705 121 040Email: ola.skanung@cyxone.com Adelgatan 21211 22 Malmöwww.cyxone.com About CyxoneCyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral